Evidence map›Paper›PMID 20889553›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2010

How immune peptidases change specificity: cathepsin G gained tryptic function but lost efficiency during primate evolution.

Wilfred W Raymond, Neil N Trivedi, Anastasia Makarova, Manisha Ray, Charles S Craik, George H Caughey

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 48 citations in OpenAlex.

  1. Trial
  2. Lubricin's Mucin Domain Has Strong Polyproline Type II Helical Character.Computational and structural biotechnology journal · 2026
    Article
  3. Species Differences in Platelet Protease-Activated Receptors.International journal of molecular sciences · 2023
    Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Mast cell proteases as pharmacological targets.European journal of pharmacology · 2016
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Wilfred W RaymondCardiovascular Research Institute, University of California at San Francisco, San Francisco, CA 94143, USA.
Neil N Trivedi
Anastasia Makarova
Manisha Ray
Charles S Craik
George H Caughey
University of California, San Francisco · USUniversity of San Francisco · USCardiovascular Institute Hospital · JPNorthern California Institute for Research and Education · US

Funding

Tools for Analysis of Airway InflammationP01HL024136 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KRUMMEL, MATTHEW F · 1985 to 2014
$23.3M
Targeting Allosteric Studies to Modulate Protein Interactions and FunctionR01AI067423 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CRAIK, CHARLES SCOTT · 2007 to 2009
$1.1M
NHLBI NIH HHS HL024136NHLBI NIH HHS P01 HL024136NIAID NIH HHS R01 AI067423
6 · The paper itself

Abstract

Cathepsin G is a major secreted serine peptidase of neutrophils and mast cells. Studies in Ctsg-null mice suggest that cathepsin G supports antimicrobial defenses but can injure host tissues. The human enzyme has an unusual "Janus-faced" ability to cleave peptides at basic (tryptic) as well as aromatic (chymotryptic) sites. Tryptic activity has been attributed to acidic Glu(226) in the primary specificity pocket and underlies proposed important functions, such as activation of prourokinase. However, most mammals, including mice, substitute Ala(226) for Glu(226), suggesting that human tryptic activity may be anomalous. To test this hypothesis, human cathepsin G was compared with mouse wild-type and humanized active site mutants, revealing that mouse primary specificity is markedly narrower than that of human cathepsin G, with much greater Tyr activity and selectivity and near absence of tryptic activity. It also differs from human in resisting tryptic peptidase inhibitors (e.g., aprotinin), while favoring angiotensin destruction at Tyr(4) over activation at Phe(8). Ala(226)Glu mutants of mouse cathepsin G acquire tryptic activity and human ability to activate prourokinase. Phylogenetic analysis reveals that the Ala(226)Glu missense mutation appearing in primates 31-43 million years ago represented an apparently unprecedented way to create tryptic activity in a serine peptidase. We propose that tryptic activity is not an attribute of ancestral mammalian cathepsin G, which was primarily chymotryptic, and that primate-selective broadening of specificity opposed the general trend of increased specialization by immune peptidases and allowed acquisition of new functions.

Indexed as

Biological EvolutionAmino Acid SequenceAnimalsCathepsin GHumansMiceMolecular Sequence DataPhylogenyPolymerase Chain ReactionPrimatesSequence AlignmentSubstrate SpecificityCathepsin G

Identifiers

PMID20889553
PMCPMC3954857
OpenAlexW2171365330

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.